Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

HBABT
87893
phase and rises in titer. The highest titers of total anti-HBc are found in the chronic HBsAg carrier state.
Total anti-HBc may be negative or undetectable in serum or plasma during the early acute phase of HBV
infection and long after infection resolution, when titers may fall. The presence of anti-HBs in serum
indicates previous exposure to HBV and acquired immunity. Low titers of anti-HBs in serum, however,
can signal a lack of immunity to future HBV infection. The clinical relevance of anti-HBs detection is in
establishing complete resolution of the infection and the acquisition of immunity, whether acquired as a
result of natural HBV infection or vaccination. Anti-HBs may fall below detectable levels with time. See
Viral Hepatitis Serologic Profiles in Special Instructions.
Reference Values:
HEPATITIS B SURFACE ANTIGEN
Negative
HEPATITIS B CORE TOTAL ANTIBODY
Negative
HEPATITIS B SURFACE ANTIBODY
Unvaccinated: negative
Vaccinated: positive
HEPATITIS B SURFACE ANTIBODY, QUANTITATIVE
Unvaccinated: or =12.0
Interpretation depends on clinical setting.
See Viral Hepatitis Serologic Profiles in Special Instructions.
Clinical References: 1. Kubo S, Nishiguchi S, Hirohashi K, et al: Clinical significance of prior
hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer
1999 September 1:86(5):793-798 2. Schiff ER: Lamivudine for hepatitis B in clinical practice. J Med
Virol 2000 July;61(3):386-391 3. Sherlock S: Hepatitis B: the disease. Vaccine 1990;8 Suppl:S6-S9
Hepatitis B Surface Antibody Monitor, Post-Transplant, Serum
Clinical Information: For patients with chronic hepatitis B virus (HBV) infection (hepatitis B
surface antigen-positive), outcomes following liver transplantation for end-stage liver disease are poor.
Recurrent HBV disease is common and associated with decreased liver graft and patient survival
(approximately 50% at 5 years). Studies have shown administration of hepatitis B immune globulin
(HBIG) in the perioperative and early posttransplant periods could delay or prevent recurrent HBV
infection in these transplant recipients. Intravenous or intramuscular administration of HBIG has
become the standard of care for these liver transplant recipients in most liver transplant programs in the
United States (US) since mid-1990. Most therapy protocols administer HBIG in high doses (10,000 IU)
during the perioperative period and first week after transplantation, with the goal of achieving serum
hepatitis B surface antibody (anti-HBs) levels of >500 mIU/mL. Serial levels of anti-HBs are obtained
to determine the pharmacokinetics of HBIG in each patient to guide frequency of HBIG dosing. There
is a high degree of variability in HBIG dosage required to achieve desirable serum anti-HBs levels
among transplant recipients during the first few weeks to months after transplantation. Patients who
were hepatitis B envelope (HBe) antigen positive before transplantation usually require more HBIG to
achieve the target anti-HBs levels, especially in the first week after transplantation. Duration of HBIG
therapy varies from 6 months to indefinite among different US liver transplant programs. Protocols
providing